|
Kyowa Hakko Kirin (formerly Kyowa Hakko Kogyo) hopes to cure what ails you. The company conducts research and development as well as production of pharmaceuticals targeting cancer, kidney disease, and immune system disorders. Its main products include those for chemotherapy-- and dialysis-related anemia, hypertension, allergies epilepsy, and other conditions. Like many other biopharma firms, Kyowa Hakko Kirin is working on producing human antibodies. It also produces diagnostic reagents. The firm does the majority of its business in Japan where it has about a dozen plants and labs; it also has operations in China, the UK, and the US.
|
| | | Contact Information | |
Address: |
1-6-1, Ohtemachi, Chiyoda-ku
Tokyo 100-8185, Japan
| | Phone: | +81-3-3282-0007 | | Fax: | +81-3-3284-1968 |
|
| Financial
Highlights | | Fiscal Year End: | March | | Revenue (2011): | 4440.20 M | | Revenue Growth (1 yr): | (-12.50%) | | Employees (2011): | 7,229 | | Employee Growth (1 yr): | (-3.40%) |
|
|
Key People
| | • |
CEO and Director:
Yuzuru Matsuda
|
|
|
Industry Information
| |
Sector: | |
Industry: |
|
|
